CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.2 If approved, CagriSema would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment
Chronic Inflammation Linked to Metabolic and Heart Disease Chronic inflammation creates a domino effect: It stiffens arteries, triggering high blood pressure and a greater risk of heart attacks and strokes. Cells become more resistant to insulin, making diabetes more likely and harder to control
VEGF promotes angiogenesis, the formation of new blood vessels, which is critical for delivering oxygen and nutrients to recovering brain tissue
Analysis of mutants disrupted in bacillithiol metabolism in Staphylococcus aureus
Developments have been made to create glutathione supplements specifically designed to absorb well